Session 1. Therapeutic Opportunity    |    Chair: Tae Heung Kang (Director, Prestige Biopharma IDC)

Ayami Okuzumi

Juntendo University

Session 2. Therapeutic Modality    |    Chair: Yeon Sook Lee (Director, Prestige Biopharma IDC)          

Tae Dong Han

Abtis

Session 3. Open Innovation    |    Chair: Yong-Woo Kim (Head, Busan Center for Creative Economy & Innovation)

Christophe Lanneau

Genopole, France

Session 1. Therapeutic Opportunity   
Chair: Tae Heung Kang (Director, Prestige Biopharma IDC)

Bok Hwan Chun

Korea Drug Development Fund

Min Soo Kim

University of Rochester Medical Center

Yoon Joo Choi

Chonnam National University

Ayami Okuzumi

Juntendo University

Session 2. Therapeutic Modality
Chair: Yeon Sook Lee (Director, Prestige Biopharma IDC)

Jin Keon Pai

Innocure Therapeutics

Tae Ho Hwang

Bionoxx

Tae Dong Han

Abtis

Joon Seok Park

Daewoong Pharmaceutical

Hak Zoo Kim

Seoul Bio Hub

Danny Belkin

SingHealth, Singapore

Christophe Lanneau

Genopole, France